Artemisinin, a sesquiterpene lactone produced by Artemisia annua glandular secretory trichomes, is the active ingredient in the most effective treatment for malaria currently available. We identified a mutation that disrupts the amorpha-4,11-diene C-12 oxidase (CYP71AV1) enzyme, responsible for a series of oxidation reactions in the artemisinin biosynthetic pathway. Detailed metabolic studies of cyp71av1-1 revealed that the consequence of blocking the artemisinin biosynthetic pathway is the redirection of sesquiterpene metabolism to a sesquiterpene epoxide, which we designate arteannuin X. This sesquiterpene approaches half the concentration observed for artemisinin in wild-type plants, demonstrating high-flux plasticity in A. annua glandular trichomes and their potential as factories for the production of novel alternate sesquiterpenes at commercially viable levels. Detailed metabolite profiling of leaf maturation time-series and precursor-feeding experiments revealed that nonenzymatic conversion steps are central to both artemisinin and arteannuin X biosynthesis. In particular, feeding studies using 13 C-labeled dihydroartemisinic acid (DHAA) provided strong evidence that the final steps in the synthesis of artemisinin are nonenzymatic in vivo. Our findings also suggest that the specialized subapical cavity of glandular secretory trichomes functions as a location for both the chemical conversion and the storage of phytotoxic compounds, including artemisinin. We conclude that metabolic engineering to produce high yields of novel secondary compounds such as sesquiterpenes is feasible in complex glandular trichomes. Such systems offer advantages over single-cell microbial hosts for production of toxic natural products.
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artemisinin | p450 oxidase | terpenoid | sesquiterpene | Artemisia annua T he sesquiterpene lactone artemisinin is the active ingredient in artemisinin-combination therapies-the most effective treatment for malaria currently available. The production of artemisinin occurs in specialized 10-cell biseriate glandular trichomes present on the leaves, stems, and inflorescences of Artemisia annua (1) (2) (3) . Artemisinin is phytotoxic (4) and is believed to accumulate in the subapical extracellular cavity of glandular trichomes (2) . This ability of trichomes to transfer compounds into extracellular cavities (5, 6) overcomes the problem of cellular toxicity. Conveniently, natural products located in these cavities are readily extractable as exemplified by artemisinin. This natural product is extracted on a commercial scale by submerging intact dried A. annua leaf material in organic solvent with the active ingredient being directly crystallized from the condensed organic fraction (7) . There has been much interest in determining the steps involved in the biosynthesis of artemisinin in recent years, largely driven by efforts to produce this compound through a completely biosynthetic microbial-based fermentation route (8, 9) . Presently microbial production is at best semisynthetic, terminating at artemisinic acid (AA), which must then be extracted from culture and chemically converted to artemisinin by using photooxidation (8, 10) . The lack of a low-cost, scalable conversion process is considered to be a major factor in the failure so far of the semisynthetic route to sustainably impact the market, making it uncompetitive with plant-based production (11) .
Although the enzymatic steps involved in production of the nonphytotoxic precursors amorpha-4,11-diene (A-4,11-D) and dihydroartemisinic acid (DHAA) have been elucidated (12) (13) (14) (15) and the associated genes have been shown to be highly expressed in both the apical and subapical cells of the glandular secretory trichomes (3, 16) , the final steps in the conversion of DHAA to artemisinin are considered to be nonenzymatic and may be extracellular (17, 18) . Therefore, microbial-based "complete" synthetic biology routes to artemisinin may never be achievable. Meanwhile, modern molecular breeding has succeeded in improving A. annua (19) , creating hybrids reaching artemisinin yields of 1.4% dry leaf biomass in commercial field trials (20) (www.artemisiaf1seed.org/).
The glandular secretory trichomes of A. annua produce almost 600 secondary or specialized metabolites, many of which are terpenoids (21) . These include a significant number of terpene allylic hydroperoxides and endoperoxides (21) . This latter class, of which artemisinin is a member, are typically bioactive and therefore potential targets for development as pharmaceuticals (22) . Consistent with their phytochemical complexity, it is known that glandular secretory trichomes express multiple members of gene families, encoding enzymes of specialized metabolism, including terpene synthases and cytochrome P450 oxidases (16, 19, 23) . Many of these enzymes are considered to be promiscuous (24) . We reasoned that this plasticity could be exploited by developing biochemical knockouts, redirecting flux to new highvalue sesquiterpenes in a proven plant production system. Recent attempts to knock down the A-4,11-D synthase by using RNAi in self-pollinating A. annua resulted in only a modest (30-50%) reduction in artemisinin levels (25) . We have chosen to target amorpha-4,11-diene C-12 oxidase (CYP71AV1), which catalyzes the three-step conversion of A-4,11-D to AA (13, 26, 27) .
Significance
The antimalarial artemisinin is a sesquiterpene lactone produced by glandular secretory trichomes on the leaves of Artemisia annua. Using a mutant impaired in artemisinin synthesis, we demonstrate the importance of nonenzymatic conversions in terpenoid metabolism and highlight the ability of A. annua glandular secretory trichomes to redirect flux into a sesquiterpene epoxide. The research presented offers insight into the mechanism of the final steps of artemisinin synthesis in A. annua, with significant implications for future production of secondary compounds in native versus heterologous host systems.
When we knocked out this enzyme, as expected, artemisinin was not produced; however, rather than A-4,11-D accumulating, it was instead readily converted to a sesquiterpene epoxide, arteannuin X. Detailed metabolite analysis revealed that production of this compound paralleled the production of artemisinin during leaf maturation, with early steps occurring in young leaves and later steps in older leaves. Our findings confirm the function of the CYP71AV1 enzyme in planta and also demonstrate the flexibility of glandular secretory trichome biochemistry, such that it is capable of redirecting the flux of A-4,11-D into a sesquiterpene epoxide at levels similar to artemisinin.
Results and Discussion
Disruption of CYP71AV1 Results in the Accumulation of a Sesquiterpene
Epoxide at the Expense of Artemisinin. We used the TILLING method (28) to screen for mutations in the single-copy (Fig. S1 ) CYP71AV1 gene in an F2 population of A. annua that had been derived from an ethyl methane sulfonate (EMS)-mutagenized population of the Artemis F1 hybrid, as described (19) . This process resulted in an allelic series of 10 mutants, of which just 1 was nonsense because of a G-to-A transition in the second exon of CYP71AV1 (Fig. S2A ). This mutation, which we designate cyp71av1-1, gives a predicted conversion of amino acid Trp-124 in the polypeptide to a stop codon, resulting in a major truncation of the enzyme and loss of most of the putative heme-binding sites, as well as Ser-473, which is crucial for catalyzing oxidation reactions ( Fig. S2 B and C).
Previous work had shown that early stage intermediates in the artemisinin pathway accumulate in young A. annua leaves, and, as they mature, artemisinin accumulates (25, 29) . To investigate the effects of the cyp71av1-1 mutation on artemisinin biosynthesis, we analyzed three leaf developmental stages: juvenile (leaves 1-5 as counted down from the apical meristem), expanding (leaves 7-9), and mature (leaves 11-13). To generate material for this analysis, we backcrossed cyp71av1-1 to Artemis parents, selfed the progeny, and performed DNA marker-based selection of wild-type (WT), heterozygous, and homozygous cyp71av1-1 individuals from the segregating backcrossed F2 population (Fig. S3 ). We did not detect any morphological differences between WT and cyp71av1-1 material (Fig. S4 ). We also extended the analysis to include oven-dried leaf material stripped from entire plants to investigate metabolite conversions occurring after harvest.
Compared with WT and heterozygous material, the juvenile leaves of cyp71av1-1 contain significantly elevated levels of the first committed metabolite in the artemisinin pathway, A-4,11-D ( Fig. 1 A, i and Dataset S1), consistent with the reported in vitro activity of CYP71AV1 (13, 26, 27) . Metabolite profiling further revealed a complete loss of all metabolites downstream of A-4,11-D including artemisinin, which typically accumulate in juvenile, expanding and mature WT leaves ( Fig. 1 A, ii-viii and C and Datasets S2 and S3).
Other classes of secondary metabolites, including aromatic alcohols and ketones, coumarins, monoterpenes, and other sesquiterpenes remained largely unchanged in cyp71av1-1 (Datasets S1 and S3). However, levels of some minor monoterpenes (eucalyptol, borneol, and sabinene) and sesquiterpenes (calarene, α-bisabolol, and cedrenol,) were reduced, and levels of two minor flavonoids (retusin and artemetin) were increased in cyp71av1-1 (Datasets S1 and S3). These and other changes were largely restricted to the juvenile leaves (Datasets S1 and S3 and Fig. S5 ), which are relatively dense in glandular trichomes (29) and exhibit high expression levels of terpene synthases (30) . Recent attempts to silence AMORPHA-4,11-DIENE SYNTHASE expression in self-pollinating varieties of Artemisia annua resulted in increased levels of two nonamorphadiene sesquiterpenes, caryophyllene and copaene, which may be due to an elevated pool of farnesyl diphosphate acting as substrate for other sesquiterpene synthases in the glandular trichomes (25) .
Ultraperformance liquid chromatography tandem mass spectrometry (UPLC-MS) analysis revealed that cyp71av1-1 leaves accumulate large amounts of an oxygenated C 14 metabolite (Dataset S3, Peak_ID M221.1535T43). One-dimensional (1D) and 2D NMR (spectroscopic techniques were used to elucidate the structure of this amorphadiene sesquiterpene as (2S,3R,6S)-3-methyl-6-(2R-methyloxiran-2-yl)-2-(3-oxobutyl) cyclohexanone, which we refer to as arteannuin X (Fig. 1 A, ix and B) . At 0.4% leaf dry weight in mature leaves the concentration of arteannuin X in cyp71av1-1 is almost half that of artemisinin in WT leaves and the developmental profile for accumulation in expanding and mature leaves is similar for both compounds (Fig. 1 A, ix and Dataset S3). The fact that arteannuin X is present in trace amounts in WT and heterozygous cyp71av1-1 material (Fig. 1 A, ix and Dataset S3) suggests that it normally occurs as a byproduct of A-4,11-D oxidation. In vivo and in vitro formation of low abundance by-products derived from other intermediates of artemisinin synthesis have been reported (12, 17, 18) .
NMR analysis of cyp71av1-1 extracts identified a second major compound, A-4,11-D tertiary allylic hydroperoxide (A-4,11-DOOH; Fig. 1 A, x and B) that had not previously been reported in WT A. annua. The pattern of accumulation of A-4,11-DOOH ( Fig. 1 A, x) preempted that of arteannuin X reaching a concentration of almost 0.15% leaf dry weight in juvenile and expanding leaves of cyp71av1-1 before decreasing in mature leaves ( Fig. 1 A, x) . Although A4,11-DOOH was sufficiently stable to survive the chromatographic isolation procedures that were required to obtain it in a pure state for analysis by NMR, it was found to be unstable under prolonged storage in deuterated chloroform, where it spontaneously converted to arteannuin X. This finding provided circumstantial evidence that arteannuin X might be biosynthesized from A-4,11-D via its tertiary hydroperoxide (A-4,11-DOOH) in vivo, in much the same way that DHAA has been shown to be transformed to artemisinin via the tertiary allylic hydroperoxide of DHAA, dihydroartemsinic acid tertiary hydroperoxide (DHAAOOH) (17) .
In Planta Similarities Between the Synthesis of Arteannuin X and Artemisinin. Using UPLC-MS, we compared the conversion profile of A-4,11-D to arteannuin X in leaves with that of DHAA to artemisinin. Specifically, we also monitored DHAAOOH, the final intermediate in the in vivo production of artemisinin ( Fig. 1  A, iv and B) . We found that DHAAOOH levels peak in expanding WT leaves at a concentration of 0.5% leaf dry weight ( Fig. 1 A, iv and Dataset S3). Artemisinin levels increase gradually from juvenile to mature leaves, reaching a maximum concentration of 1.2% dry leaf weight and remaining stable during the postharvest drying process. (Fig. 1 A, iv and Dataset S3). Previous work has shown that the DHAAOOH intermediate can also give rise to both dihydro-epi-deoxyarteannuin B (DHEDB) (31) , and (by Hock-cleavage) deoxyartemisinin (17) . Although DHEDB remains at a concentration threefold lower than artemisinin throughout leaf maturation and after harvest (Fig. 1 A, vi and Dataset S3), the levels of deoxyartemisinin increase during dry leaf storage, accumulating to 0.1% leaf dry weight (Fig. 1 A, vii and Dataset S3). These data suggest that, after harvest, any remaining DHAAOOH is preferentially converted to deoxyartemisinin rather than artemisinin.
We next carried out a more detailed analysis of the progression during leaf maturation of A-4,11-D to either arteannuin X or artemisinin in cyp71av1-1 and WT, respectively, by performing 1 H NMR analysis on individual extracts from a 24-leaf maturation series (Fig. 2) . Determination of the relative amounts of the three most abundant sesquiterpene metabolites associated with cyp71av1-1 (A-4,11-D; A-4,11-DOOH; and arteannuin X) revealed a progressive decline in A-4,11-D, which was matched by an increase in arteannuin X. This analysis also demonstrated that the amount of A-4,11-DOOH reaches a maximum in leaves 7-8 ( Fig. 2A) . This pattern is entirely consistent with our hypothesis that A-4,11-D is converted to arteannuin X via the intermediate A-4,11-DOOH. 1 H NMR analysis of WT material clearly demonstrated that a decline in DHAA inversely correlates with an increase in artemisinin, which reaches a maximum at leaves 14-15, whereas the DHAAOOH intermediate peaks around leaves 7-8 ( Fig. 2B) , as for A-4,11-DOOH.
The results of the above experiments revealed clear parallels in the conversion of A-4,11-D to arteannuin X via the hydroperoxide intermediate (A-4,11-DOOH) and the final steps in the conversion of DHAA to artemisinin via DHAAOOH. There is strong in vivo and in vitro evidence for a nonenzymatic autoxidation Fig. 1 . Effects of cyp71av1-1 mutation on selected sesquiterpene levels in fresh and dried leaves. (A) Level of selected sesquiterpenes were quantified by GC-MS (i) and UPLC-MS (ii-x) in fresh leaf (L) 1-5 (juvenile), 7-9 (expanding), and 11-13 (mature) as counted from the apical meristem, plus oven-dried whole plant-stripped leaves (dry) from 12-wk-old glasshouse-grown homozygous (hom), heterozygous (het) cyp71av1-1, and segregating WT as described in SI Materials and Methods. Error bars represent SEM (n = 15 for L1-5, L7-9, and L11-13; n = 6 for dry leaf). Letters represent Tukey's range test results after one-way ANOVA or restricted maximum likelihood (see SI Materials and Methods for details). Groups not sharing letters indicate statistically significant differences. (B) Summary of the effects of cyp71av1-1 mutation on the level of selected sesquiterpenes. Red cross indicates steps of the pathway targeted by cyp71av1-1 mutation. Full arrows, known enzymatic steps; dotted arrows, potential nonenzymatic conversions; brown dotted arrows, novel pathway operating in the cyp71av1-1 mutant; full green arrows, metabolite changes (all types of leaves). AAA, artemsinic aldehyde; AAOH, artemsinic alcohol; ALDH1, aldehyde dehydrogenase; AMS, amorpha-4,11-diene synthase; ArtB, arteannuin B; CPR, cytochrome P450 reductase; DBR2, artemisinic aldehyde Δ 11(13) reductase; DeoxyArt, deoxyartemisinin; DHAAA, dihydroartemsinic aldehyde; DXR, 1-deoxy-Dxylulose-5-phosphate reductoisomerase; DXS, 1-deoxy-D-xylulose-5-phosphate synthase; FPP, farnesyl diphosphate; FPS, farnesyl diphosphate synthase; G-3-P, glyceraldehyde-3-phosphate; HDR, 4-hydroxy-3-methylbut-2-enyl diphosphate reductase; HMG-CoA, 3-hydroxy-3-methylglutaryl-CoA; HMGR, 3-hydroxy-3-methylglutaryl CoA reductase; MEcPP, 2-C-methyl-D-erythritol-2,4-cyclopyrophosphate; MEP, 2-C-methylerythritol 4-phosphate; MVA, mevalonate.
of DHAA to DHAAOOH and subsequent nonenzymatic rearrangement to artemisinin (17) . Our data suggest that a similar autooxidation operates in cyp71av1-1 to convert A-4,11-D to A-4,11-DOOH and on to arteannuin X. The spontaneous conversion of A-4,11-DOOH to arteannuin X in deuterated chloroform noted above is entirely consistent with this hypothesis. A speculative pathway to account for this conversion is detailed in Fig. S6 .
In Vivo Evidence for Nonenzymatic DHAA Conversion in cyp71av1-1 and WT Trichomes. Previous reports have suggested that peroxidase and/or dioxygenase enzymes may be involved in the conversion of DHAA to artemisinin (16, 32) . To further investigate DHAA conversion, we fed [U- 13 C 15 ]-DHAA to boiled, intact, and dark-incubated trichomes that had been isolated from cyp71av1-1 (which lacks endogenous DHAA) and WT leaves (see SI Materials and Methods and Figs. S7-S9 for details). Chloroform extracts of [U- 13 C 15 ]-DHAA-fed trichomes and no-trichome controls were subjected to UPLC-MS analysis, and the mass spectrum of each sesquiterpene 12 C monoisotope metabolite was used to predict the mass spectra expected from the corresponding [U- 13 C 15 ]-isotopomer. Metabolite concentrations were first normalized to the trichome density for a given sample. Because DHAA can slowly degrade and convert spontaneously to "downstream" products over time, labeled metabolite concentrations in trichome samples were also corrected by subtracting concentrations measured in matched time-equivalent buffer controls. (Fig. 3) .
It was found that [U-
13
C 15 ]-artemisinin did not accumulate substantially over the 5-d feeding period in extracts of [U- 13 C 15 ]-DHAA-fed trichomes in either cyp71av1-1 or WT leaves (Fig. 3  A and B , white, red, and black triangles). Lack of artemisinin accumulation in trichomes fed with [U- 13 C 15 ]-DHAA is perhaps not surprising, because previous results have indicated that DHAAOOH cannot efficiently undergo Hock cleavage into artemisinin in an aqueous environment (such as trichome extraction buffer) and that it may preferentially form DHEDB (17) . We found an accumulation of [U- 13 C 15 ]-DHEDB in extracts from both light-incubated boiled and intact trichomes from cyp71av1-1 and WT leaves (Fig. 3 A and B , white and red squares). Dark-incubated samples did not show an accumulation of the [U- 13 C 15 ]-labeled DHEDB (Fig. 3 A and B , black squares), leading us to conclude that DHEDB formation is lightdependent. Both cyp71av1-1 and WT trichomes showed very similar patterns of [U- 13 C 15 ]-DHEDB accumulation, which reached a plateau between 2 and 3 d after feeding commenced (Fig. 3 A and B, white and red squares). It is also evident that boiling accelerates the formation of DHEDB in both cyp71av1-1 and WT trichomes (Fig. 3 A and B, red vs. . white squares), consistent with the process being nonenzymatic. We did not detect labeled DHAAOOH itself, which suggests that the experimental conditions favored rapid conversion of this intermediate through to DHEDB.
To investigate whether uptake of [U- 13 C 15 ]-DHAA into isolated trichomes is a limiting factor in the feeding experiment, we fed the labeled substrate to crude protein extracts from isolated trichomes. The products and temporal pattern of their accumulation was very similar to that obtained for the intact trichome feeding (Fig. 3 C and D) . Notably, there was no accumulation of [U- 13 C 15 ]-artemisinin over the 5-d feeding period (Fig. 3 C and D, red, black, and white triangles), whereas [U- 13 C 15 ]-DHEDB accumulated in both light-incubated boiled and nonboiled protein extracts from cyp71av1-1 and WT trichomes (Fig. 3 C and D , red and white squares). It is also evident that boiling accelerates the formation of DHEDB in both cyp71av1-1 and WT trichome protein extracts (Fig. 3 C and D , red vs. white squares), consistent with the process being nonenzymatic.
The intact trichome-feeding and trichome protein extractfeeding experiments demonstrate that in cyp71av1-1, a block in artemisinin and DHEDB biosynthesis can be rescued by direct feeding of DHAA, which is expected, given the role of CYP71AV1 in the artemisinin biosynthetic pathway (Fig. 1B) . The lack of further accumulation of artemisinin over a 5-d period in trichomes maintained in an aqueous medium contrasts with the gradual accumulation of artemisinin in trichomes during leaf maturation ( Figs. 1 and 2 ). These observations lead us to suggest that the nonaqueous environment present in the intact subapical cavity of glandular secretory trichomes is essential for the efficient conversion of DHAA to artemisinin via DHAAOOH. In the absence of such an environment, DHAA is instead converted to DHEDB in a light-dependent nonenzymatic process.
The hydrophobic nature of A-4,11-D prevented us from preparing aqueous solutions of [U- 13 C 15 ]-A-4,11-D for trichomefeeding experiments and performing a similar analysis of arteannuin X in the cyp71av1-1 mutant.
Given that the final steps in artemisinin biosynthesis appear to be nonenzymatic, the question arises as to how its production during leaf maturation is controlled. It is reasonable to assume that active transport system(s) will be responsible for pumping artemisinin precursors into the subapical cavity of glandular secretory trichomes. Transport of DHAA into the subapical cavity could be a limiting factor, with spatial and temporal expression patterns of relevant transporters controlling the increase in artemisinin during leaf maturation (Fig. 2B ).
Conclusion
We have described an A. annua CYP71AV1 knockout mutant that provides in planta confirmation for the function of this enzyme. The cyp71av1-1 mutant accumulates high levels of A-4,11-D, which is converted to arteannuin X, a nor-seco-amorphane sesquiterpene epoxide. This work clearly demonstrates the plasticity of metabolism in the glandular secretory trichomes of A. annua; when one pathway is blocked, novel sesquiterpene alternatives are produced, highlighting the potential of trichomes as factories for production of new compounds with potential medicinal and industrial applications.
We found that the in vivo oxidation of A-4,11-D to arteannuin X parallels that of DHAA to artemisinin during the progression of leaf maturation. We were able to chemically complement cyp71av1-1 by externally feeding DHAA to intact trichome preparations and trichome protein extracts. This finding demonstrated that the conversion of DHAA to DHEDB, via a tertiary allylic hydroperoxide, is a nonenzymatic, light-requiring process. The lack of accumulation of artemisinin in these experiments supports the idea that a nonaqueous environment, as provided by the subapical cavity of glandular secretory trichomes, is essential for the nonenzymatic production of the endoperoxide containing artemisinin from DHAA. Together, these findings highlight the importance of nonenzymatic conversions in terpenoid metabolism of A. annua glandular secretory trichomes. These findings, together with the observation that artemisinin is known to be cytotoxic to various cell types (4, 33, 34) , suggest a functional requirement for the specialized subapical cavity as a location for both chemical conversion and storage. It also highlights the challenges of producing certain types of plant natural products in microbial systems that lack this level of structural complexity and the need for more research into the compartmentation of metabolic processes in plant production systems.
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